

11th World Congress and Expo on Cell & Stem Cell Research

March 25-26, 2019 | Orlando, USA

KEYNOTE FORUM | DAY 2

JOURNAL OF CELL SCIENCE & THERAPY, VOLUME: 10 | DOI: 10.4172/2157-7013-C1-048

Life, blood and eye tests to complement stem cell therapy

Critical to broad acceptance of newer technologies is an understanding of the causes behind both success and failure of treatments. As humans age, their immune system undergoes immunosenescence. The progressive deterioration of the immune system is one contributing factor to the characteristic decline in stem cell activity that also accompanies aging, at least with regard to certain types of stem cells. Underlying low-grade chronic disease and accompanying immune activation and inflammation also drive senescence processes and concomitantly impacts stem cell efficacy. It's well established that inflammatory sites and an inflammatory milieu are hostile towards the survival of transplanted cells. Practitioners who apply stem cell therapy have a significant opportunity to take a leading role in understanding and reversing accelerated aging. Stem cell therapy, to be most impactful, should be delivered

along with anti-inflammatory strategies. Key to this approach is understanding the immune system/inflammatory status of each patient. Presented here is a novel Harvard Medical School and MIT developed a systems approach to accurately and precisely measure immune and chronic inflammatory status. The Chronic Disease Assessment™ and Chronic Disease Temperature™ provide a subjective and objective measure of immune status and include a path to reducing inflammation. The eye plays an important role in this program. Cataract, for example, is a sign of systemic inflammation, stem cells disease, high cardiovascular risk, and early mortality. The lens of the eye uniquely acts like a single large stem cell. The connection between life risks, biomarkers and eye pathologies will be discussed in the context of a holistic approach to successful stem cell therapy.

Biography

Thomas J Lewis is a Medical Scientist. He holds a PhD in Chemistry from MIT and certification from the Harvard School of Public Health. He is an entrepreneur and healthcare professional with expertise in toxic substances, drug development,



Thomas J Lewis
Health Revival Partners; TN
USA

biotechnology, health technology and medical protocol development. For the past decades, he has worked closely with senior researchers and clinicians at Harvard Medical School and has developed a program for chronic disease root cause prevention, screening, diagnosis and treatment. Alzheimer's disease and the most serious eye diseases, macular degeneration and glaucoma have been a particular focus. He has opened the first-of-its-kind Alzheimer's prevention, screening, early detection and treatment centre in the Orlando, Florida area in 2014. He works closely with Dr. Clement Trempe, 41 years at Harvard Medical School who is one of few doctors in the world who treats chronic eye diseases as systemic inflammatory conditions – and reverses these conditions with great success. It was through this work that Dr Trempe developed his protocol for diagnosing, treating and reversing Alzheimer's disease that is now an integral part of the Health Revival offering.

tlewis@healthrevivalpartners.com